Literature DB >> 8427984

Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein.

D Campana1, E Coustan-Smith, A Manabe, M Buschle, S C Raimondi, F G Behm, R Ashmun, M Aricò, A Biondi, C H Pui.   

Abstract

Overexpression of bcl-2 delays the onset of apoptosis in lymphohematopoietic cells. We measured levels of bcl-2 protein in normal and leukemic human B-cell progenitors with a specific monoclonal antibody and flow cytometry. Normal immature B cells had low levels of bcl-2 protein; the intensity of fluorescence, expressed as molecules of soluble fluorochrome per cell, within CD10+ cells was 3,460 +/- 1,050 (mean +/- SD; 5 samples). In 16 cases of B-lineage acute lymphoblastic leukemia (ALL), cells had levels of bcl-2 that were strikingly higher than those of their normal counterparts (33,560 +/- 14,570; P < .001 by t-test analysis). We next investigated whether the intensity of bcl-2 expression correlated with the resistance of immature B cells to in vitro culture. In 12 cases of B-lineage ALL, the cells recovered after 7 days of culture on allogeneic bone marrow stromal layers were 69% to 178% (median, 95.5%) of those originally seeded. Prolonged survival of leukemic cells in vitro was observed even in the absence of stromal layers in 6 of these 12 cases; the intensity of bcl-2 protein expression in these cases was 45,000 +/- 13,270, compared with 21,500 +/- 7,260 in the 6 cases in which greater than 99.5% of cells rapidly died by apoptosis under the same culture conditions (P = .003). Five immature B-cell lines, continuously growing in the absence of stroma, had the highest bcl-2 expression (79,400 +/- 20,330). By contrast, most normal CD19+, sIg-immature B cells died despite the presence of bone marrow stromal layers; 9.7% to 28.2% were recovered after 7 days of culture in three experiments. We conclude that abnormal bcl-2 gene expression influences the survival ability of B-cell progenitors. This may contribute to leukemogenesis and explain the aptitude of leukemic lymphoblasts to expand outside the bone marrow microenvironment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427984

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells.

Authors:  Tadi Satish Kumar; Vijayalakshmi Kari; Bibha Choudhary; Mridula Nambiar; T S Akila; Sathees C Raghavan
Journal:  J Biol Chem       Date:  2010-08-10       Impact factor: 5.157

Review 2.  Manipulating the apoptotic pathway: potential therapeutics for cancer patients.

Authors:  Darcy J P Bates; Lionel D Lewis
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

3.  New markers for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Christopher Clark; Laura Key; Peixin Liu; Mohammad Mehrpooya; Patricia Stow; Xiaoping Su; Sheila Shurtleff; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

4.  The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies.

Authors:  Kristy Lee; Margaret M Briehl; Andrew P Mazar; Ines Batinic-Haberle; Julio S Reboucas; Betty Glinsmann-Gibson; Lisa M Rimsza; Margaret E Tome
Journal:  Free Radic Biol Med       Date:  2013-02-14       Impact factor: 7.376

Review 5.  Apoptotic cell signaling in cancer progression and therapy.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  Integr Biol (Camb)       Date:  2011-02-22       Impact factor: 2.192

Review 6.  Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.

Authors:  Alisa B Lee-Sherick; Rachel M A Linger; Lia Gore; Amy K Keating; Douglas K Graham
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

7.  Harnessing the cell death pathway for targeted cancer treatment.

Authors:  Christina K Speirs; Misun Hwang; Sungjune Kim; Weier Li; Sophia Chang; Vinod Varki; Lauren Mitchell; Stephen Schleicher; Bo Lu
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

8.  Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.

Authors:  Dimitrios Korbakis; Andreas Scorilas
Journal:  Tumour Biol       Date:  2012-01-12

9.  FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

Authors:  Qing Liu; Xiaobin Zhao; Frank Frissora; Yihui Ma; Ramasamy Santhanam; David Jarjoura; Amy Lehman; Danilo Perrotti; Ching-Shih Chen; James T Dalton; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-08-29       Impact factor: 22.113

Review 10.  Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

Authors:  Min H Kang; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.